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Background: Interest in mobile apps that support long-term conditions such as asthma is matched by recognition
of the importance of the quality and safety of apps intended for patient use. We assessed how changes over a
2-year period affected the clinical suitability of apps providing self-management information and tools for people
with asthma by updating a review first performed in 2011.
Methods: Systematic content assessment of all apps for iOS and Android examining the comprehensiveness of
asthma information, consistency with the evidence base for asthma self-management and adherence to best
practice principles for trustworthy content, comparing the quality of apps available in 2011 to those released since.
Results: Between 2011 and 2013, numbers of asthma apps more than doubled from 93 to 191, despite withdrawal
of 25% (n = 23/93) of existing apps. Newer apps were no more likely than those available in 2011 to include
comprehensive information, such as the use of action plans, or offer guidance consistent with evidence; 13%
(n = 19/147) of all apps, and 39% (n = 9/23) of those intended to manage acute asthma, recommended self-care
procedures unsupported by evidence. Despite increases in the numbers of apps targeting specific skills, such as
acute asthma management (n = 12 to 23) and inhaler technique (from n = 2 to 12), the proportion consistent with
guidelines (17%, n = 4/23) and inhaler instructions (25%, n = 3/12), respectively, was low, and most apps provided
only either basic information about asthma (50%, n = 75/147) or simple diary functions (24%, n = 36/147).
Conclusions: In addition to persisting questions about clinical quality and safety, dynamic aspects of app turnover
and feature evolution affect the suitability of asthma apps for use in routine care. The findings underline the need
for coordinated quality assurance processes that can adapt to changing clinical and information governance-related
risks, ensure compliance with the evidence base and reflect local variations in clinical practice. It is unclear if substantial
clinical benefits can be realized from a landscape dominated by low quality generic information apps and tools that do
not adhere to accepted medical practice.
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Medical apps for patients are software programs that
run on personal mobile devices and offer functions such
as disease tracking, access to clinical and peer support,
health information, and reminders [1]. Survey data indi-
cate that approximately three fifths of US and UK adults
own an app-capable smartphone [2,3] and around half
of adults report knowing about and using apps [2]. In
2012, a fifth reported having downloaded a health or fit-
ness app, increasing amongst people with recent changes
in health status [4]. Industry estimates suggest that, by
2018, over one billion individuals worldwide will use a
health or fitness app [5] drawn from a pool of consumer
health apps estimated to number in excess of 15,000 [6].
In 2014, over a third of US clinicians reported having
recommended an app to a patient in the past year [7],
and a survey of US adults suggested that nine of ten
would use one issued ‘on prescription’ by a healthcare
professional [8]. Among policymakers and clinicians,
interest in apps reflects the potential to improve patient
support and, potentially, health outcomes by equipping
individuals with tools for self-management and remote
monitoring [9-11]. However, there is also increasing rec-
ognition of the importance of ensuring that medical apps
are effective [12,13], safe [14,15], meet patient needs
[16,17], and comply with existing evidence-based clinical
practice [18-20].
In 2011, we mapped [21] the types of apps available
for patients with asthma, chosen as a prevalent long-
term condition with potential social and economic
[22,23] impacts and which requires a range of self-
management skills in everyday life [24]. We explored the
degree to which apps conformed to evidence-based rec-
ommendations derived from international asthma guide-
lines. We characterized the range of possible functions
supported by apps for asthma, including information
provision, peak flow and symptom diaries, and medica-
tion trackers. While highlighting the potential to support
tailored education and assist clinical decision-making
using monitoring data, the review uncovered a range of
potential issues. Few information apps addressed key
educational topics recommended in international guid-
ance. Many advocated strategies for acute asthma man-
agement and trigger avoidance that were unsupported
by current evidence. Assessment and diagnostic tools
were largely unvalidated, some had errors of design, and
the small number of apps offering therapeutic interven-
tions had no basis in evidence.
Rapid evolution is characteristic of mobile technolo-
gies. New hardware and software capabilities create op-
portunities for health; for example, remote monitoring
enabled by always-on network connections and wearable
sensors [25]. Modern development methods mean
that apps commonly undergo cycles of refinement inresponse to testing and user feedback [26]. Changes in
mobile devices and software have been accompanied by a
broadening discussion about quality and safety that has in-
volved clinicians [27,28], policy groups [29], and, more re-
cently, regulators [30,31]. Compared to 2011, there is
greater understanding of potential risks and more re-
sources targeted towards medical app developers, aiming
to improve the quality of medical apps [32-35]. As a result,
there is an opportunity to explore the impact that these
changes may have had on apps intended for patient use.
We aimed to explore changes in the content, function,
and clinical quality of apps since 2011. We used a sys-
tematic approach, based on a systematic literature re-
view, to identify, classify, and review apps for asthma. By
updating our earlier review, we sought to differentiate




All apps from the two most widely-used [36] mobile
platforms (Android and iOS) incorporated in the original
review [21] were automatically eligible for inclusion. We
chose not to include apps running on other platforms,
such as Blackberry, whose market share is currently de-
clining [36]. To identify new apps, we performed a step-
wise process of search, screening, and review. We
searched the public app stores of the two most popular
smartphone operating systems using the terms ‘asthma’,
‘inhaler’, ‘peak flow’, and related word variants, e.g., ‘asth-
matic’. After removing apps already included from the pre-
vious study, results were screened to eliminate obviously
irrelevant content. The remaining apps were downloaded
and reviewed to reach a final decision for inclusion.
Screening and review were performed by three reviewers
(KH, JO, and AG), working independently. Final decisions
were reached by consensus.
Free and paid-for smartphone and tablet apps were eli-
gible for inclusion if they contained asthma-specific con-
tent or tools intended for use by patients or the public
(see list below). Apps targeted exclusively towards clini-
cians were not included. Apps were excluded if they
could not be downloaded from UK app stores or, after at
least two attempts on different test devices, would not
start. Apps from any country were eligible provided they
supported English.
Inclusion criteria
 Smartphone or tablet app
 Free or paid
 Running on Android or iOS platforms
 Content or tools addressing one or more aspects of
asthma diagnosis, management, or support as either
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related elements can be isolated from the rest of the
content
 Presenting content in any format
 English language
 Targeted at patients of any age
Exclusion criteria
 Not available through an approved device
marketplace
 Explicitly disclaimed use for a health-related purpose
 Could not be downloaded because of country
restrictions that prevented access in the UK
 Could not be used because of technical problems,
after two attempts
App assessment
Apps were assessed using a systematic approach to
characterize functions and content. Apps containing in-
formation about asthma were evaluated using a set of
criteria derived from US [37], UK [24], and international
[38] asthma guidelines. Information content was evalu-
ated for coverage of eight domains identified as priorities
for self-management education (basic facts about asthma,
basic principles of treatment, trigger avoidance, how to
use treatment, self-monitoring skills, the role of action
plans, managing exacerbations, and personalized care),
using a set of operational criteria derived from guidelines.
These criteria were those used in our earlier review except
for one criterion in the self-monitoring domain which was
modified in response to peer feedback to acknowledge
symptom-based methods for self-monitoring (criteria and
change detailed in Additional file 1: Table AF1). Coverage
of each educational domain was rated as either complete
(all criteria satisfied), partial (some criteria satisfied), or
absent. Content was also evaluated for consistency with
evidence-based recommendations concerning eight as-
pects of asthma management derived from guidelines
(Additional file 1: Table AF2). For those apps with content
addressing a particular topic, the advice given was rated as
being either consistent or inconsistent with underlying
evidence. Consistency was judged both on the basis of
factual accuracy and appropriate qualification of advice to
reflect either uncertainty or limitations in the applicability
of evidence, such as recommendations relevant only to
individuals with more severe asthma, in which case we ex-
pected any information to be appropriately qualified. In-
formation content was evaluated regardless of the delivery
medium. However, apps focusing only on complementary
and alternative medicine, using the definition of the NIH
National Center for Complementary and Alternative
Medicine [39], were excluded from this analysis because
there was no basis to expect that they should comply withguideline recommendations. For diaries and other self-
management tools, the nature of inputs and outputs and
methods for summarizing and sharing data were charac-
terized. For all apps with calculator and questionnaire
functions, we attempted to locate validation information
in the form of an authoritative citation. Where validation
information was found, the behaviour of the app in hand-
ling inputs and producing appropriate outputs was
assessed. All apps were assessed for compliance with prin-
ciples for ethical disclosure of authorship and data protec-
tion practices, using criteria previously adapted from
those assessing online health information devised by the
Health on the Net Foundation [40] (criteria in Additional
file 1: Table AF3). We also recorded any software issues
that were encountered during testing, using a schema
devised during the first review to classify problems
such as crashes or errors in the user interface (detailed in
Additional file 1: Table AF4).
Apps included in the original review had previously
been assessed using these criteria. To ensure scoring
consistency, we conducted a process of calibration in
which a random selection of 10 apps was re-assessed
and the outcomes compared to previous judgments.
Apps that had been updated between 2011 and 2013
were also reassessed. Apps were reviewed by an author
of the original review (KH) and one of two additional re-
viewers (JO and AG), working independently. After rec-
onciliation, the results of the assessment process were
recorded, along with basic characteristics of included
apps, in a structured data extraction form (template in
Additional file 1: Table AF5) for analysis.
Post hoc evaluation
In addition to the planned analyses described above, we
performed a post hoc evaluation of inhaler technique
guidance in response to the growing number of apps
that include this function, using criteria derived from
manufacturer guidance to assess key steps, such as in-
haler preparation, necessary for effective drug delivery
into the lungs (detailed in Additional file 1: Table AF6).
Data analysis
Apps available on multiple platforms were grouped for
subsequent analysis. When an app was available as mul-
tiple versions on the same platform, for example ‘demo’
and ‘full’ editions, the most fully featured version was
used for analysis (irrespective of free/paid status). The
decision to define the unit of analysis as the platform-
independent app reflected learning from the original re-
view concerning the possible risk of bias resulting from
double counting some apps. In that review, we treated
each app version separately because we anticipated dif-
ferent quality issues arising from the need to tailor each
app according to the platform and version. However, the
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case. While in 2011 only a small number of apps were
affected (n = 13), and sensitivity analysis undertaken dur-
ing that analysis demonstrated minimal impact on re-
sults, by 2013 the number of duplicates was substantially
larger (n = 77) with consequently greater scope for bias.
Descriptive statistics were used to summarize the
types, functions, and quality characteristics of apps avail-
able in 2011, those released since 2011, and overall.
When reporting comparisons between 2011 and 2013,
data are always written in chronological order, e.g., for
“(X vs. Y)”, X are data from 2011 and Y reflect data for
apps released since 2011. We hypothesized that newer
apps might have different quality characteristics arising
from greater experience amongst developers and dis-
course in both medical and computer science literature
emphasizing the importance of high-quality medical
apps. To explore differences in the quality of informa-
tion apps, we compared the proportion of educational
domains completely, partially, or not satisfied, and the
proportion of guidance consistent with the evidence base
in those available in 2011 and those released since. We
also compared the proportion of apps satisfying principles
for ethical disclosures of information and the proportion
of apps with specific software issues. Apart from these
planned comparisons, we performed a small number of
additional tests to compare differences in the proportion
of paid-for apps, apps addressing complementary and al-
ternative medicine, and the incorporation of features such
as support details, in-app help, and social sharing features.
These are marked as post hoc comparisons in the results.
For all comparisons, we used a two-tailed Fisher’s
exact test [41], with the Freeman-Halton extension [42]
to handle two by three cases for information compre-
hensiveness and (post hoc) content orientation. To adjust
for multiple comparisons, we used a Holm-Bonferroni
[43] sequential adjustment to control the group-wise
error rate at 5%, instead of specifying a fixed significance
level for comparisons. All analyses were performed using
R (Version 3.1.2).
Results
Searches performed in June, July, and August 2013 iden-
tified 764 apps (Figure 1, n = 538 Android, 226 Apple).
After excluding unsuitable apps (n = 643), 191 apps were
selected for evaluation. These included 70 apps identi-
fied in the 2011 review that remained available. Details
of apps excluded at the final review stage are provided in
Additional file 2: Table AF7.
The number of apps for asthma more than doubled
between 2011 and 2013 (from 93 to 191), dominated by
growth in apps available for Android (from 41 to 103,
151% increase, vs. iOS 52 to 88, 69% increase, charted
over time in Figure 2). Forty-one apps were available onboth Android and iOS platforms and a further 36 had
multiple versions on a single platform. After removing
24 platform duplicates and 20 demonstration versions
where a more fully-featured version was available, ana-
lysis was performed on 147 unique apps. Over a quarter
(28%, n = 22/78 unique apps) included in the original re-
view had been withdrawn, and a similar proportion
(24%, n = 19/78) updated, between 2011 and 2013. With-
drawals are included in reported 2011 statistics but not
in overall 2013 totals. At the conclusion of analysis in
June 2014, a further 20 apps had been withdrawn. These
are retained for analysis, but annotated as withdrawn in
data tables provided in Additional file 2.
Table 1 summarizes the basic characteristics of in-
cluded apps. Compared to apps available in 2011, apps
released since were significantly more likely to be free
(33%, n = 26/78 vs. 64%, n = 59/92, P <0.001, post hoc)
but also more likely to carry advertising (18%, n = 14/78
vs. 34%, n = 31/92, P = 0.024, post hoc), although the dif-
ference was not significant after sequential adjustment.
Between 2011 and 2013 the median cost of paid-for apps
decreased from £1.27 GBP to £0.89 (£1.12 overall),
reflecting a reduction in the proportion of apps charging
more than £1.00 (37%, n = 29/78 vs. 22%, n = 20/92).
The proportion of apps offering in-app upgrades to un-
lock addition functions remained unchanged at 9% (n =
13/147) overall, (8%, n = 7/78 vs. 7%, n = 6/92, P = 0.576,
post hoc). While the US remained the main source of
apps for asthma, accounting for almost half of apps with
a known country of origin available in 2013 (48%, n =
52/108), the number of countries represented increased
from 13 to 21. Although the overall proportion of apps
indicating that the product was targeted at a particular
group remained low (16%, n = 24/147), apps released
since 2011 were significantly more likely to provide in-
formation targeting parents/caregivers (4%, n = 3/78 vs.
16%, n = 15/92, P = 0.011, post hoc). There was also a
non-significant increase in the proportion of apps target-
ing children (3%, n = 2/78 vs. 8%, n = 7/92, P = 0.182,
post hoc).
Information provision remained the function most
commonly offered by nearly three fifths of apps for
asthma (56%, n = 83/147; Table 2), followed by self-
management tools in almost half (48%, n = 70/147). The
number of apps combining self-management tools, such
as diaries, with any form of information content grew
from one (1%) in 2011 to nine (6%) in 2013. As in 2011,
small numbers of apps available in 2013 provided func-
tions for assessing asthma symptoms using question-
naires (n = 11) or sensors (n = 2) or assisting with
aspects of therapy (n = 6). Although there was an in-
crease in the proportion of apps released since 2011 in-
corporating mixed content addressing both conventional
and alternative medical traditions, the change in relative
Figure 1 Flowchart of app selection process. Flowchart details the process of selecting individual apps for inclusion in the study. After
evaluation of 191 apps, duplicates available on both iOS and Android (n = 24) and, when more fully featured versions were available, ‘lite’ or
demonstration versions (n = 20) were excluded, leaving 147 unique apps for subsequent analysis.
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Table 2) and the overall proportion of apps presenting
content oriented towards conventional medical practice
changed minimally (69% n = 101/147 vs. 73% n = 57/78
in 2011).Figure 2 Growth in numbers of asthma apps. Plot shows the total num
release date, for the period 2009 to mid-2013. Withdrawals are accounted f
were not available for 5 apps; therefore, final n = 186.Information apps
The number of apps offering information about asthma
increased from 37 in 2011 to 83 by 2013, with 60 new
apps and 14 withdrawals. Most information apps avail-
able in 2013 incorporated general information aboutber of available apps for asthma against time, based on the original
or. Vertical lines indicate the dates of the 2011 and 2013 surveys. Data
Table 1 Basic characteristics of included apps
2011 (n = 78) New 2013 (n = 92) ¤ All 2013 (n = 147) ¤
Characteristic Yes % Yes % Yes %
Platform
Android only 32 41% 52 57% 73 50%
iOS only 40 51% 28 30% 57 39%
Both 6 8% 12 13% 17 12%
Cost
Free 26 33% 59 64% 80 54%
Paid-for 52 67% 33 36% 67 46%
Median £1.27 – £0.89 – £1.12 –
Country of origin†
US 24 31% 31 34% 52 35%
UK 5 6% 6 7% 8 5%
India 7 9% 7 8% 8 5%
Australia 3 4% 4 4% 7 5%
Other 10 13% 24 26% 33 22%
Unknown 29 37% 20 22% 39 27%
Content orientation
Conventional medicine only 56 72% 59 64% 101 69%
Complementary/alternative medicine only 15 19% 17 18% 26 18%
Mixed 7 9% 16 17% 20 14%
Audience targeting‡
Children or young adults 2 3% 7 8% 8 5%
Parents or caregivers 3 4% 15 16% 19 13%
No audience stated 73 94% 73 79% 123 84%
Other features
Adverts 14 18% 31 34% 39 27%
Social sharing 13 17% 35 38% 61 41%
Cloud storage 3 4% 10 11% 16 11%
Clinical disclaimer 32 41% 37 40% 55 37%
In-app help 14 18% 28 30% 43 29%
Online help 5 6% 6 7% 10 7%
¤ New 2013, Apps available in 2013 that were not available in 2011; All 2013, All apps available in 2013, excluding those available in 2011 that were
subsequently discontinued.
†Four countries with highest overall number of apps in 2013 shown. Other countries were: Ireland (n = 5), Germany (n = 4), Switzerland (n = 4), Japan (n = 3),
Romania (n = 2), Singapore (n = 2), Austria (n = 1), France (n = 1), Italy (n = 1), Norway (n = 1), Poland (n = 1), Portugal (n = 1), Spain (n = 1), and Sweden (n = 1).
‡Audience targeting was identified by specific claims made in the app title or description or content. We found no cases where apps explicitly indicated they
were intended for adult use only. A small number of apps targeted both children and a parent or caregiver (2011, n = 0; New 2013, n = 3; All 2013, n = 3).
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of apps (23%, n = 18/78 vs. 34%, n = 31/92, P = 0.174,
post hoc) also incorporated specific instructions about
the management of acute asthma, inhaler technique, and
other aspects of self-management (discussed further in
Therapeutic Instructions and Tools, below.) Apps used a
range of media to communicate information including
text (64%, n = 53/83), video and animation (10%, n = 8/83),
or by combining different media types (27%, n = 22/83).
A significantly greater proportion of apps released since2011 used a medium other than text to communicate
information (11%, n = 4/37 vs. 42%, n = 25/60, P = 0.001,
post hoc). A new development was the use of gameplay
(n = 3) to provide interactive education in three prod-
ucts targeted at children and teenagers. Full details of
information-containing apps are provided in Additional
file 2: Table AF8.
Although increasing in number, the proportion of
products presenting information based exclusively
around conventional medical practices was unchanged
Table 2 Breakdown of app functions
By date† By platform
2011 (n = 78) New 2013 (n = 92) ¤ All 2013 (n = 147) ¤ All 2013 (n = 191)
Function n % n % n % Android iOS
Information 37 47% 60 65% 83 56% 66 44
General information 36 46% 51 55% 74 50% 56 39
Acute asthma management (First aid) 12 15% 18 20% 23 16% 19 14
Inhaler technique guidance 2 3% 10 11% 12 8% 6 13
Other therapeutic instructions 13 17% 10 11% 16 11% 15 9
Self-management tools 36 46% 38 41% 70 48% 42 49
Diaries and trackers 21 27% 18 20% 36 24% 23 26
Pollen status 3 4% 8 9% 12 8% 6 10
Pollution status 3 4% 6 7% 9 6% 2 9
Allergen database 4 5% 3 3% 7 5% 5 4
Forum 0 0% 1 1% 1 1% 1 0
Online pharmacy 0 0% 1 1% 1 1% 1 0
Combined with information 1 1% 8 9% 9 6% 6 7
Assessment tools 9 12% 8 9% 16 11% 10 11
Physiological measurement 2 3% 1 1% 3 2% 0 4
Assessment questionnaires 4 5% 7 8% 11 7% 7 9
Standalone calculators 2 3% 2 2% 4 3% 3 1
Therapeutic tools 2 3% 5 5% 6 4% 1 5
The table compares the types of functions present in apps for asthma available in 2011 and 2013, and provides a breakdown by platform for 2013; 25 apps
included in the 2011 assessment were withdrawn and this accounts for the lower overall total in 2013. Some apps contained multiple functions and are counted
more than once.
†Apps available on both Android and iOS are counted only once.
¤ New 2013, Apps available in 2013 that were not available in 2011; All 2013, All apps available in 2013, excluding those available in 2011 that were
subsequently discontinued.
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all apps available in 2013 (23%, n = 19/83) combined al-
ternative and conventional information and the remain-
der (28%, n = 23/83) presented information based on
alternative medical principles alone. Consequently, there
were 59 apps (vs. 23 in 2011) incorporating conventional
medical information for which it was possible to assess
coverage of self-management education topics and
consistency with guideline recommendations.
Over two thirds (83%, n = 49/59) of all apps available
in 2013 provided at least some details about basic as-
pects of asthma pathophysiology (Table 3). However,
only just over half provided information about basic
principles of medical management (53%, n = 31/59), and
fewer addressed key self-management skills, including
allergen and trigger avoidance (44%, n = 26/59), self-
monitoring skills (39%, n = 23/59), or how to use treat-
ment appropriately (39%, n = 23/59). Less than a third of
apps addressed how to recognize the signs of deterior-
ation (31%, n = 18/59), the importance of personalized
treatment and goal setting (31%, n = 18/59), and the role
of an action plan (22%, n = 13/59). There was no signifi-
cant difference in the proportion of apps released since2011 addressing domains other than basic facts (27%,
n = 6/22 vs. 20%, n = 9/45, P = 0.542), nor in the propor-
tion of apps addressing each domain considered indi-
vidually (P values shown in Table 3). While the overall
number of products addressing three or more educa-
tional domains, at least partially, grew from 14 to 31 be-
tween 2011 and 2013, new apps were not more likely
to address multiple domains (64%, n = 14/22 vs. 51%
n = 23/45, P = 0.435). In the same period, the number of
products addressing all eight domains at least partially
grew from two to five (with one withdrawal). As in 2011,
however, no product provided complete coverage of all
eight domains by satisfying all criteria.
Thirty-six apps (vs. 14 in 2011) were evaluated for
consistency of recommendations against nine evidence-
based topics (Table 4) because they contained content
addressing at least one topic. Smoking cessation and
passive smoking avoidance were the topics most com-
monly addressed by apps (by n = 19 and 21, respectively)
and, as in 2011, were correctly recommended as benefi-
cial by all apps. All apps addressing immunotherapy
(n = 5) and weight reduction (n = 7) correctly advocated
their use in specific patient populations. However, apps
Table 3 Coverage of asthma self-management education topics by information apps
2011 (n = 23) New 2013 (n = 44) ¤ All 2013 (n = 59) ¤
Educational topic No Partially Wholly %† No Partially Wholly % P value‡ No Partially Wholly %
Basic facts about the nature of the condition 2 15 6 91% 9 26 9 80% 0.510 10 37 12 83%
Allergen and trigger avoidance 9 12 2 61% 25 19 0 43% 0.094 33 24 2 44%
The nature of treatment: relievers and
preventers
11 7 5 52% 22 18 4 50% 0.333 28 25 6 53%
Recognizing and responding appropriately
to acute exacerbations
14 7 2 39% 30 9 5 32% 0.728 41 12 6 31%
How to use treatment 16 6 1 30% 27 17 0 39% 0.259 36 22 1 39%
Self-monitoring and assessment skills 16 6 1 30% 27 16 1 39% 0.632 36 20 3 39%
The role of a written, personalized action plan 18 2 3 22% 34 5 5 23% 1.000 46 6 7 22%
Personalizing the definition of good asthma control 17 5 1 26% 29 15 0 34% 0.244 41 18 0 31%
The table compares the proportion of apps containing asthma self-management education information that address guideline-recommended topics either
partially or wholly between 2011 and 2013. Apps focusing solely on complementary and alternative medicine were excluded.
†The proportion of information apps that wholly or partially address a given educational topic.
‡Two-tailed probability obtained from the Freeman-Halton extension to Fisher’s exact test of the comparison of topic coverage in apps available in 2011 and those
released subsequently. After applying a Holm-Bonferroni correction to control the family-wise error rate at less than or equal to 5%, no comparisons
achieved significance.
¤ New 2013, Apps available in 2013 that were not available in 2011; All 2013, All apps available in 2013, excluding those available in 2011 that were
subsequently discontinued.
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unclear evidence of benefit, such as mold (n = 12/12)
and cockroach (n = 7/7) avoidance measures, removal of
pets (n = 7/8), and avoidance of air pollution (n = 15/17).
Most apps covering seasonal influenza vaccination rec-
ommended it (n = 8/10) without acknowledging the
uncertain impact on asthma [44]. Compared to 2011,
there were no significant differences in the proportion
of apps released since that presented advice consistent
with the evidence base, either when considering eachTable 4 Consistency of information apps with evidence-based
2011
Statement n† C
Removal of pets from the home (Qualified benefit) 3 1
Fungal allergen avoidance and control measures (Qualified benefit) 8 0
Cockroach avoidance and control measures (Qualified benefit) 6 0
Cessation of active smoking (Beneficial) 7 7
Avoidance of passive smoking (Beneficial) 8 8
Avoidance of exposure to air pollution (Qualified benefit) 8 1
Immunotherapy in atopic asthma (Beneficial) 1 1
Weight reduction in obese patients (Beneficial) 3 3
Seasonal influenza vaccination (Qualified benefit)** 4 1
The table compares the proportion of apps containing particular management advi
2013. The expected advice is shown in parentheses. We use the term ‘qualified ben
or aspects of personal choice, are relevant concerns and unconditional recommend
and alternative medicine were excluded. Statistical comparison between apps in 20
comparisons, performed using Fisher’s exact test, yielded an exact probability of 1.0
†The number of apps that took a stance on a given topic, for example, by stating th
‡The proportion of apps whose stance is consistent with the evidence base.
¤ New 2013, Apps available in 2013 that were not available in 2011; All 2013, All ap
subsequently discontinued.
**Seasonal influenza vaccination is routinely offered to asthmatic patients; however
asthma exacerbations [44].statement individually (exact P values computed from
proportions shown in Table 4 were all 1.0) or when
comparing the proportion of apps containing no state-
ments contradicting evidence (36%, n = 5/14 vs. 43%,
n = 12/28, P = 0.747). A new finding in 2012 concerned a
small number apps (n = 6) containing advice emphasiz-
ing the possible harmful effects of conventional medi-
cine and, in two cases, promoting a commercial product,
for example a homeopathic remedy. Previously, apps
containing mixed content had tended to emphasize therecommendations
New 2013 ¤ All 2013 ¤
onsistent %‡ n Consistent % n Consistent %
33% 7 1 14% 8 1 13%
0% 9 0 0% 13 0 0%
0% 4 0 0% 7 0 0%
100% 14 14 100% 19 19 100%
100% 15 15 100% 21 21 100%
13% 14 1 7% 17 2 12%
100% 4 4 100% 5 5 100%
100% 4 4 100% 7 7 100%
25% 8 2 25% 10 2 20%
ce that is consistent with evidence-based recommendations between 2011 and
efit’ when additional factors, such as personal sensitivity to particular allergens
ations are therefore inappropriate. Apps focusing solely on complementary
11 and new apps in 2013 was performed but is not shown because all
.
at a given action is definitely effective in controlling asthma symptoms.
ps available in 2013, excluding those available in 2011 that were
, it is unclear if vaccination reduces the severity or frequency of flu-related
Huckvale et al. BMC Medicine  (2015) 13:58 Page 9 of 15right to choose between medical approaches rather than
denying accepted medical practice.
Diaries and trackers
Thirty six apps available in 2013 (24%, vs. 27% in 2011)
were diaries for recording asthma symptoms (n = 27),
peak flow measurements (n = 24), and medication (n = 24,
detailed in Additional file 2: Table AF9). Six apps allowed
a user to document an action plan. Six incorporated in-
haler trackers, including two where this was the sole func-
tion, designed to alert a user when a metered dose inhaler
or other medication was running low. One app connected
to an electronic inhaler to automatically log doses. Two
thirds of diaries (67%, n = 24/36) offered a mechanism to
summarize either recorded symptoms (n = 4), peak flow
(n = 11), or both (n = 9) in chart form. Over half (55%
n = 11/20) of apps charting peak flow used predicted
(n = 6), personal best (n = 7), or manually entered (n = 3)
thresholds to classify charted data to aid interpretation,
for example, as ‘green’, ‘yellow’, and ‘red’ zones. Nine apps
provided alerts based on changing input values. Seven
provided specific advice, either by excerpting relevant
parts of a user supplied-action plan (n = 3/6 apps with
action plan support) or displaying standardized text
(n = 4). Sixteen allowed reminders to be set to take peak
flow measurements (n = 9), medication (n = 3), appoint-
ments (n = 2), and vaccination (n = 1). Compared to
2011, there were increases in the proportion of apps
synchronizing and storing data online (10%, n = 2/21 vs.
44%, n = 8/18, P = 0.025, post hoc) but not those offering
a mechanism for sharing data with clinicians (62%,
n = 13/21 vs. 61%, n = 11/18, P = 1.000, post hoc), for ex-
ample, email or file export.
Other self-management tools
Nineteen apps (compared to 6 in 2011, Table 2) provided
status information about pollen (n = 10), air pollution (n
= 7), or both (n = 2; Additional file 2: Table AF10). Most
(n = 12) provided coverage of locations in the US. Only
one product, which relied on used-supplied data, offered
global coverage. Seven apps (vs. 4 in 2011) offered data-
bases of chemical additives to allow patients to identify
potential triggers in food and cosmetic ingredients. One
app combined an electronic version of an action plan
with links to information about asthma. Another prod-
uct connected to a forum where users could view topics
about asthma management and post their own ques-
tions. A third app offered UK patients the ability to pur-
chase asthma medication online.
Diagnostic and assessment tools
Fifteen apps (vs. 6 in 2011) contained diagnostic or assess-
ment functions. Ten products offered questionnaires for
asthma diagnosis (n = 4) or assessment (n = 6; Additionalfile 2: Table AF11). Two apps used the validated Asthma
Control Test under license and one app reused a ques-
tionnaire developed by the University of Maryland. The
remaining apps either did not provide a citation or valid-
ation information or the information provided was insuffi-
cient to verify the basis for assessment. Nine products
provided predicted peak flow calculators as either the
main function (n = 3) or integrated into a diary (n = 6). No
calculator app provided a clear citation, but the underlying
formula was identified for two apps. Issues first identified
in 2011 resulting in incorrect calculation output for two
apps where the formula was deduced were unresolved.
Three products used the device microphone to attempt to
quantify lung volume (n = 1) and analyse breath sounds
(n = 2), but were either unvalidated or experimental prod-
ucts that had not yet received regulatory approval.
Therapeutic instructions and tools
Forty-one apps (28% of n = 147) contained specific in-
structions for the use of inhalers (8%, n = 12/147), first aid
for acute exacerbations (16%, n = 23/147), or other ap-
proaches to the management of asthma such as the use
of herbal remedies (11%, n = 16/147, breakdown in
Additional file 2: Table AF12). After pressurized metered
dose inhalers (pMDI), either alone (100%, n = 12/12) or
with spacer devices (92%, n = 11/12), the devices most
commonly addressed by inhaler technique guidance were
Accuhalers (58%, n = 7/12) and Turbohalers (50%, n = 6/
12), although a range of additional devices were also cov-
ered (Additional file 2: Table AF12). Apps used text (33%,
n = 4/12), video (25%, n = 3/12), animation (8%, n = 1/12),
or a combination (33%, n = 4/12) to provide guidance. Post
hoc evaluation (criteria in Additional file 2: Table AF6) ex-
amined the proportion of apps providing complete and
correct information about inhaler preparation (67%, n = 8/
12), positioning in the mouth (67%, n = 8/12), and the se-
quence of inhalation and actuation (50%, n = 6/12). While
a quarter (25%, n = 3/12) addressed all three domains, the
majority of apps omitted or misstated at least one step ne-
cessary for effective delivery of drugs to the lungs [45,46]
for at least one of the inhalers discussed. The most com-
mon error (in 25%, n = 4/12) was the failure to explain
how inspiration should start before, and continue after, ac-
tuation of a pMDI. A variable proportion of apps ad-
dressed other aspects of inhaler use such as holding the
breath after inhalation (83%, n = 10/12), timing of a sec-
ond dose (58%, n = 7/12), and mouth rinsing to reduce the
risk of candidiasis with inhaled steroids (50%, n = 6/12).
While five apps (42%) provided information about identi-
fying empty Turbohalers or Accuhalers, no app addressed
dose-tracking using pMDI. The two apps (17%) that cov-
ered inhaler care both provided incorrect information
about spacer cleaning that risked static build-up interfer-
ing with subsequent doses.
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ment of acute asthma, approximately half (52%, n = 12/23)
provided a clear description of the signs of acute asthma
and gave practical advice such as sitting a patient up (48%,
n = 11/23) and offering reassurance (52%, n = 12/23).
Three fifths (61%, n = 14/23) provided appropriate instruc-
tions about when to seek further help. While almost two
thirds (65%, n = 15/23) recommended the use of a rescue
inhaler, less than a third (30%, n = 7/23) provided specific
dose and timing instructions and only four apps (17%)
provided instructions appropriate for children in addition
to adults. Overall, four apps (17%) addressed all five com-
ponents (Additional file 2: Table AF12). The proportion of
apps released since 2011 that made treatment recommen-
dations based on alternative medical practices did not
change significantly (76%, n = 13/17 vs. 56%, n = 14/25, P
= 0.207, post hoc), and almost three fifths of apps available
in 2013 (58%, n = 19/33), and 39% (n = 9/23) of those
intended to manage acute asthma, recommended proce-
dures unsupported by evidence, for example, the use of a
hot water bottle to warm the chest, cider vinegar adminis-
tered orally, or fasting for the duration of an attack.
A small number of products (n = 6 vs. 2 in 2011) were
tools intended to have a therapeutic effect. Three apps
provided training in aspects of Buteyko breathing, which
may have a future role in asthma management [47]. The
remaining three were based on alternative medical princi-
ples using hypnosis, mantra, and motivational messages.
Disclosures and software issues
Results of assessment for compliance with ethical disclo-
sures about authorship and data protection are summa-
rized in Table 5 (based on criteria detailed in Additional
file 1: Table AF4). Perhaps reflecting the increase in apps
syncing data to a cloud service (4%, n = 3/78 vs. 11%, n =
10/92, P = 0.145, post hoc) or offer social sharing (17%,
n = 13/78 vs. 38%, n = 35/92, P = 0.002, post hoc), apps re-
leased since 2011 were significantly more likely to have a
privacy policy (9%, n = 7/78 vs. 36%, n = 33/92, P <0.001).
New apps were also significantly more likely to provide
contact details (41%, n = 32/78 vs. 64%, n = 59/92, P =
0.003). While no apps in 2011 had an editorial or advertis-
ing policy, five new apps did. In general, apps provided
limited information about the information sources used
for the advice they contained. The proportion of apps
providing any kind of content attribution was unchanged
(36%, n = 21/78 vs. 33%, n = 26/92, P = 0.856). Almost three
fifths of information-containing apps (57%, n = 47/83) avail-
able in 2013 repackaged content available freely online from
resources such as Wikipedia, a small increase from 2011
(54%, n = 19/35). The majority (77%, n = 36/47) of these
apps did so without referencing the original content
sources. Overall, 35% (n = 29/83) were ‘junk’ apps that
reused, without attribution, information of generally lowquality that was freely available online in a paid-for or
advert-supported format.
We also assessed software issues encountered during
the test process (using criteria detailed in Additional
file 1: Table AF5). Compared to 2011, there was no
change in the proportion of new apps lacking appropri-
ate data entry validation to prevent, for example, textual
data being entered in numeric data fields (33%, n = 9/27
vs. 32%, n = 8/25, P = 1.000). The proportion of apps
with problems with the user interface, such as mis-
labelled data fields (32%, n = 25/78 vs. 37%, n = 34/92,
P = 0.522), or core functionality, such as the correct op-
eration of a calculator (17%, n = 13/78 vs. 10%, n = 9/92,
P = 0.252), was also unchanged. However, there was a
significant increase in apps released since 2011 experien-
cing network problems when trying to access online
content or services (4%, n = 3/78 vs. 22%, n = 20/92,
P <0.001). Crashes affected about one in ten apps during
testing, unchanged from 2011 (9%, n = 13/147 overall).
Discussion
Our updated findings present a mixed picture for clini-
cians interested in integrating apps into routine care.
While choice has increased, newer apps for asthma were
no more likely than those available in 2011 to satisfy
evidence-based recommendations for information con-
tent or the design of self-management tools. Our data
extend findings of low overall compliance with evidence
in recent assessments of medical apps for disease-
management [20,48] and health-promotion [49,50] by
suggesting that issues of quality are sustained and are
not isolated to first-generation apps. However, as in
2011, our results question the scope for benefit offered
by current apps for asthma. Firstly, rather than focusing
on known gaps in self-management where there is evi-
dence that intervention can improve outcomes, such as
the use of action plans [22,51], most apps offer either
very basic background information about asthma or sim-
ple peak flow diaries. Only a fifth of information apps
available in 2013 addressed action plans and the propor-
tion of diaries offering a mechanism for recording a plan
was smaller. Secondly, although it is recognized that in-
formation provision alone has a limited impact on health
behaviour [52], the proportion of apps combining infor-
mation and tools remains small. While apps using multi-
media methods, such as video and gameplay, presented
welcome new opportunities for tailored support that
focuses on specific needs, such as improving inhaler
technique [53], or on specific groups, such as those with
limited literacy [54], our assessment highlights the risk
of clinically-relevant impacts resulting from inadequate
content. For example, three quarters of inhaler training
apps left out at least one step considered necessary for
effective delivery of drug into the lungs. Thirdly, while
Table 5 Summary of ethical disclosures and software issues
2011 (n = 78) New 2013 (n = 92) ¤ All 2013 (n = 147) ¤
Quality domain Yes %† Yes % P value‡ Yes %
Ethical disclosures
Attribution of authorship§ 21 36% 26 33% 0.856 40 33%
Purpose clearly stated 69 88% 88 96% 0.090 141 96%
Privacy policy available 7 9% 33 36% <0.001* 44 30%
Information versioning 1 1% 3 3% 0.626 4 3%
Contact details provided 32 41% 59 64% 0.003* 90 61%
Funding model clear 21 27% 30 33% 0.502 49 33%
Editorial/advertising policy 0 0% 5 5% 0.063 5 3%
Software issues
Data entry validation issues** 9 33% 8 32% 1.000 16 33%
Functionality issues 13 17% 9 10% 0.252 15 10%
User interface issues 25 32% 34 37% 0.522 45 31%
Crashes 8 10% 8 9% 0.796 13 9%
Network issues 3 4% 20 22% <0.001* 25 17%
Other issues 10 13% 18 20% 0.301 28 19%
The table compares the proportion of apps satisfying best practices for content attribution and ethical disclosures (detailed in Additional file 1: Table AF3), and
those with software issues identified during testing (detailed with examples in Additional file 1: Table AF4), between 2011 and 2013.
†The proportion of information apps that satisfy a particular domain. Unless otherwise stated, the denominator is the total number of apps shown in the
relevant heading.
‡Two-tailed probability obtained from Fisher’s exact test of the comparison of topic coverage in apps available in 2011 and those available since 2013. *After
applying a Holm-Bonferroni correction to control the family-wise error rate within each domain at less than or equal to 5%, three comparisons were significant.
§Denominator for proportions reflects only apps with attributable content, e.g., written information, measurement scales, pollen/pollution data. Attribution of the
software itself lies with the developers whose details are always released. Denominators: 2011 n = 59, New 2013 n = 80, 2013 n = 120.
¤ New 2013, Apps available in 2013 that were not available in 2011; All 2013, All apps available in 2013, excluding those available in 2011 that were
subsequently discontinued.
**Data entry validation concerns steps taken to prevent out-of-range or inappropriate data being stored in an app, for example, textual values allowed in a
numeric field. As a result, the denominator reflects only apps permitting data entry, e.g., calculators, diaries. Denominators: 2011 n = 27, New 2013 n = 25,
2013 n = 49.
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that could plausibly play a role in interventions designed
to improve asthma self-management, apps themselves
do not currently provide effective scaffolding to support
individuals in changing, and sustaining, behaviour. For
example, although many apps offered the ability to send
data by email, and the proportion of apps using a mech-
anism to share data online almost doubled between
2011 and 2013 to 52%, no app offered a built-in mech-
anism for communication between a professional and
patient, potentially limiting the scope for feedback that
could assist self-management. Nor was it clear that the
online services linked to currently available apps could
support the kind of summary and flagging activities ne-
cessary to manage cohorts rather than single patients.
Evidence is needed that app-supported remote monitor-
ing can generate reliable data, prompt consistent and
sustained clinical improvements, and meet the needs of
patients across the spectrum of asthma severity [55]. Al-
though more apps allowed information to be shared
using a social network like Facebook or Twitter, this was
never in the context of a structured activity relating to
asthma self-management and no apps took advantage ofthe possibilities for peer support. Similar to the findings
of others [19,56], only one asthma app appeared to be
linked to an active research project [57], highlighting a
broader disconnect between guidance on the design of
interventions that incorporate evidence-based compo-
nents and evaluation [58] and what occurs in practice.
Dynamic aspects of the asthma app marketplace, in-
cluding rapid growth and turnover, have potential conse-
quences for both clinical services and individuals. Over a
quarter of apps included in the original review, including
those from reputable content providers, had been with-
drawn. While patients may choose apps to suit their
changing needs, the costs associated with app selection,
staff training, setting up support mechanisms, and ap-
propriate governance create incentives for planned care
to be based around small numbers of trusted apps. Un-
expected withdrawal of an app may be an inconvenience
for individual users, but can threaten the function of an
established clinical service. App updates are also poten-
tially disruptive, requiring testing and training. As a re-
sult, formal arrangements with app developers, such as
service-level contracts, should be considered where apps
are being used as part of planned care. Systematic
Huckvale et al. BMC Medicine  (2015) 13:58 Page 12 of 15identification of factors influencing app lifespan would
be helpful and future work should address this.
A new finding concerned apps that repackaged existing
information either to create content focused on promot-
ing specific commercial products, or to serve as a more
general vehicle for hosting adverts operating on a pay-per-
click basis. A small number specifically emphasized nega-
tive effects associated with conventional medical practice,
with the intention of promoting commercial alternatives.
Some apps were developed using online tools that specif-
ically target developers with no or limited coding experi-
ence. Marketing materials for these tools emphasized their
ability to produce apps quickly and in number. If the goal
of these apps is simply to generate advertising revenue or
an initial purchase, content need only to appear superfi-
cially plausible. This kind of low-quality information,
coupled with high volume distribution and commercial
motive, shares similarities with spam or junk email and
websites [59]. Indeed, some apps for asthma reused mater-
ial originally produced by online content farms [60]. If
sustained, the junk medical app would be an unwelcome
development, making it harder for users to locate higher-
quality and unbiased content. Unlike the web, where
search engines tend to prioritize higher-quality content in
results [61], conventional app stores offer limited mecha-
nisms for filtering out lower quality and junk apps.
Apps offering unvalidated diagnostic, assessment, and
therapeutic functions with no basis in evidence are a
continuing issue that raises questions about patient
safety and clinical liability [62]. While some apps are
likely to fall under the scope of medical app regulation
recently proposed in both the US and Europe [30,31],
aspects of how this will work in practice are yet to be
agreed, not least because regulators must balance com-
peting demands of risk, costs, and the possible impact
on innovation [14]. As a result, rapid action appears un-
likely, even where standards already exist. For example,
while physical sensors, such as peak flow meters, are
classified as moderate risk (class 2) medical devices, nei-
ther of the two asthma apps that use a device microphone
to analyse breath sounds appear to have undergone regu-
latory approval, and both remain available in November
2014, over 1 year since guidance first came out. Regulation
is also constrained by the scope of current legislation
which applies only to apps intended to diagnose, treat, or
prevent disease. While not ruling out future changes, reg-
ulators have stated that information apps do not satisfy
this definition, even if they contain procedural guidance
such as first aid [63], and that they intend to apply discre-
tion when enforcing rules for apps that probably qualify as
medical devices but pose a low overall risk such as diaries,
pollen alerts, and inhaler trackers [14]. While ensuring
that potentially useful apps are not burdened by costly
and time-consuming approvals, some apps will fall outsideestablished reporting mechanisms that would allow a
more complete picture of risk to emerge over time. Fur-
ther work is necessary to understand the consequences of
known defects in tools such as predicted peak flow calcu-
lators and identify unanticipated risks, for example, those
arising from novel services like online pharmacies that do
not involve a usual clinician.
Our findings have relevance for emerging medical app
accreditation programs [32,64,65], which aim to reduce
the burden of assessment placed on professionals and
patients, provide recognizable badges of app quality, and
collate certified apps to make them easily accessible.
Rapid app turnover and feature evolution suggest that
accreditation processes will need to be revised regularly
and programs will need to allocate appropriate resources
to reassess their growing cohort of existing certified apps
as they are updated. Programs must also consider the
possibility of best practices that vary by location and tar-
get group. For example, some US inhaler technique
guidance apps advised actuating a metered dose inhaler
in front of an open mouth, a method not taught in UK
self-management education. The growth in connected
apps, and those based around advertiser models, high-
lights the importance of assessment processes which
examine privacy and security-related risks as personal
and medical data start to be shared online. While we did
not explore the governance arrangements of cloud-based
apps, privacy and security are topical concerns for
patients [55,66]. Additionally, recent findings highlight-
ing gaps in privacy disclosures [67,68] and security ar-
rangements [69,70] in popular health apps suggest that
further scrutiny is required. High rates of app turnover
emphasize the importance of due-diligence that focuses
on the commitment of developers to maintaining their
products. The range of functions seen within a single
long-term condition in this study highlights the potential
complexity of defining comprehensive assessment stan-
dards. Similar to the content-independent criteria ap-
plied in this study, simplified assessments which focus
on high-risk functions and proxy markers for quality,
such as the involvement of clinicians in design, have
been proposed [71,72], but their predictive validity is un-
known. While most accreditation programs appear to be
developing their own criteria, a collaborative, open
approach to standard development could share the
workload, for example, by involving professional bodies
with specific content expertise, enable transparent input
by patients, professionals, and developers, and permit
evaluation. Further work should explore the extent
to which developers can be engaged proactively to
increase awareness of accreditation requirements and
the potential value of patient and professional input
into health app design, which, in turn, may increase the
likelihood that apps meet accreditation requirements
Huckvale et al. BMC Medicine  (2015) 13:58 Page 13 of 15without potentially costly cycles of rejection and resub-
mission. Finally, because accreditation programs are vol-
untary and have yet to prove their ability to control
quality issues at scale, most health apps available in pub-
lic app stores will not be badged for quality. Patient edu-
cation could address this by, for example, explaining the
phenomenon of junk medical apps and characterizing
the risks as similar to those presented by the range of in-
formation available on the general internet.
The study used a systematic method to exhaustively
sample apps from the two most popular app stores and
included steps to minimize bias during the assessment
process. By repeating an assessment first performed in
2011, we were able to explore aspects of the dynamics of
app turnover and feature development. However, the
study had a number of limitations. Apps in languages
other than English and those available on platforms
other than Android and iOS were not included. It is pos-
sible that there are systematic differences in app quality
by language or platform that this study could not detect.
Because the study involved only two time points, there
should be substantial caution in inferring that any
changes observed are indicative of trends. Our data re-
flect issues present in apps available at particular points
in time, and while representative categories are likely to
persist, the specifics will change, necessitating updated
assessment. Finally, because of limitations in the data
provided by app stores, we were unable to precisely
quantify the scale of app use by patients nor the ways in
which apps are used. The potential for a mismatch be-
tween available features and those desired by patients
was highlighted by a recent review of apps for patients
with Parkinson’s disease [73]. Future work could explore
this issue in relation to asthma, examine whether user
reviews and ratings have any predictive validity for app
quality, and continue to develop the currently limited
evidence-base specifically addressing the design of apps
for asthma self-management [74].
Conclusions
In addition to established findings about variable clinical
quality and possible safety risks, dynamic aspects of the
asthma app marketplace, such as rapid growth and turn-
over, affect the suitability of apps for use in clinical set-
tings. Efforts to assure the quality of medical apps need
to be responsive to the changing features and risks
posed by apps, consider governance as well as clinical
factors, and recognize the differing needs of patients
using apps on their own initiative and those supported
by clinical care. Accreditation programs may need to be
supplemented by proactive intervention by regulators to
address potentially unsafe apps and advice to help pa-
tients navigate the increasing numbers of poor quality or
‘junk’ apps for asthma in general app stores.Additional files
Additional file 1: Tables AF1–6. Contains: Table AF1. Operational
criteria for assessing the comprehensiveness of asthma self-management
educational materials. Criteria covering eight key educational domains,
derived from UK British Thoracic Society/Scottish Intercollegiate Guideline
Network (BTS/SIGN), US Expert Panel Report 3 (EPR-3), and Global
Initiative for Asthma (GINA) guidelines. Table AF2. Management
strategies used to assess consistency of asthma information with
evidence-base. Strategies and evidence-base derived from UK BTS/SIGN,
US EPR-3, and GINA guidelines. Table AF3. Ethical disclosure principles
for smartphone apps. Adapted from the Health on The Net Foundation
principles for health information on the internet. Table AF4. Categories
of software issue considered during assessment. Categories used to
group any software errors, user interface problems, or other issue
encountered during testing. Table AF5. Data extraction template.
Template into which details of apps were recorded for subsequent
analysis. Table AF6. Operational criteria for assessing inhaler technique
education. Criteria covering eight domains, derived from product
manufacturer guidance and UK BTS/SIGN, US EPR-3, and GINA guidelines.
Additional file 2: Tables AF7–12. Contains: Table AF7. Characteristics
of excluded apps. Table detailing apps excluded from analysis and the
reasons for exclusion. Table AF8. Characteristics of information apps.
Table of apps containing written or multimedia information about
asthma. Detailed results of evaluation for consistency and
comprehensiveness with evidence-based guidelines and adherence
to best-practices for content development disclosures. Table AF9.
Characteristics of diary apps. Table of apps containing asthma diary
and related tracking functions. Details of diary function types, action
plan support, adherence to best-practices for content development
disclosures, and any issues identified during testing. Table AF10.
Characteristics of apps with other self-management functions. Table of
apps containing self-management functions other than diaries and
trackers such as air pollution information. Details of function types,
adherence to best-practices for content development disclosures, and
any issues identified during testing. Table AF11. Characteristics of apps
with assessment functions. Table of apps containing calculator and
questionnaire functions related to asthma diagnosis or management.
Details of function types, validation information (if identified), and
adherence to best-practices for content development disclosures and any
issues identified during testing. Table AF12. Characteristics of apps with
therapeutic instructions and functions. Table of apps with an intended
therapeutic purpose. Details of function types, validation information
(if identified), adherence to best-practices for content development
disclosures, and any issues identified during testing.
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